Categories: News

Natus Medical to Hold 2021 First Quarter Financial Results Conference Call on May 6th

PLEASANTON, Calif., April 01, 2021 (GLOBE NEWSWIRE) — Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2021 first quarter financial results after the close of the market on Thursday, May 6th. Natus management will host a conference call the same day beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss those results and to answer questions.

Individuals interested in listening to the conference call may do so by dialing 1-844-634-1441 for domestic callers, or 1-508-637-5658 for international callers, and entering reservation code 5608595. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 1-855-859-2056 for domestic callers, or 1-404-537-3406 for international callers, and entering reservation code 5608595.

The conference call also will be available real-time via the Internet at http://investor.natus.com and a recording of the call will be available on the Company’s Web site for 90 days following the completion of the call.

About Natus Medical Incorporated

Natus is a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages.

Additional information about Natus Medical can be found at www.natus.com.

COMPANY CONTACT:
Natus Medical Incorporated
Drew Davies
Executive Vice President and Chief Financial Officer
(925) 223-6700
InvestorRelations@Natus.com

Staff

Recent Posts

Genflow to Attend Healthcare Conference

Genflow to Attend the 44th Annual J.P. Morgan Healthcare Conference LONDON, UK / ACCESS Newswire…

2 hours ago

Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update

Toronto, Ontario--(Newsfile Corp. - December 10, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM)…

9 hours ago

Early Data Shows that Coverage of Saliva-Based Screenings Drives Improved Patient Engagement and Treatment Plan Acceptance

BOSTON, Dec. 10, 2025 /PRNewswire/ -- A new enhanced benefit program by Delta Dental of Massachusetts (DDMA),…

11 hours ago

Robert Half Selected by Newsweek as One of America’s Most Responsible Companies 2026

MENLO PARK, Calif., Dec. 10, 2025 /PRNewswire/ -- Global talent solutions and business consulting firm…

11 hours ago

Azenta Authorizes $250 Million Share Repurchase Program

BURLINGTON, Mass., Dec. 10, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that its…

11 hours ago